Your browser doesn't support javascript.
loading
Evaluating different breast tumor progression models using screening data.
Westvik, Åsbjørn Schumacher; Weedon-Fekjær, Harald; Mæhlen, Jan; Liestøl, Knut.
Afiliação
  • Westvik ÅS; Department of Pathology, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway.
  • Weedon-Fekjær H; Oslo Center for biostatistics and epidemiology, Research Support Services, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway. harald.weedon-fekjar@medisin.uio.no.
  • Mæhlen J; Department of Pathology, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway.
  • Liestøl K; Center of Cancer Biomedicine, Department of Informatics, University of Oslo, Norway, P.O. Box 1080 Blindern, 0316, Oslo, Norway.
BMC Cancer ; 18(1): 209, 2018 02 20.
Article em En | MEDLINE | ID: mdl-29463227
ABSTRACT

BACKGROUND:

Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors.

METHODS:

Breast cancer incidence data 1990-2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50-69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990-1998), we simulated incidence levels during the following period (1999-2009).

RESULTS:

The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels.

CONCLUSIONS:

Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Modelos Estatísticos Tipo de estudo: Clinical_trials / Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Modelos Estatísticos Tipo de estudo: Clinical_trials / Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article